

Listing of the Claims:

This listing of Claims will replace all prior versions, and listings, of claims in the application.

1. (Withdrawn) A method of treating a human suffering from a disorder associated with dyslipidemia, said method comprising administering to the subject an effective amount of a purified non-human animal ApoA-I protein.
2. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is hypercholesterolemia.
3. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is cardiovascular disease.
4. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is atherosclerosis.
5. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is restenosis.
6. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is HDL or ApoA-I deficiency.
7. (Withdrawn) The method of Claim 1 wherein the disorder associated with dyslipidemia is hypertriglyceridemia.
8. (Withdrawn) A method of treating a subject suffering from an infection, said method comprising administering to the subject an effective amount of a purified non-human animal ApoA-I protein.
9. (Withdrawn) The method of Claim 8 wherein the infection is bacterial.
10. (Withdrawn) The method of Claim 9 wherein the infection is septic shock.
11. (Withdrawn) The method of Claim 8 wherein the infection is viral.
12. (Withdrawn) The method of Claim 11 wherein the virus is influenza.

13. (Withdrawn) The method of Claim 11 wherein the virus is human immunodeficiency virus.
14. (Withdrawn) The method of Claim 11 wherein the virus is cytomegalovirus.
15. (Withdrawn) The method of Claim 11 wherein the virus is herpes simplex virus.
16. (Currently amended) A sterile pharmaceutical composition suitable for intravenous administration into a human comprising ~~a purified non-human animal Apolipoprotein A-I protein (ApoA-I protein)~~ the protein-lipid complex of Claim 17 and a pharmaceutically acceptable carrier, excipient or diluent.
17. (Currently amended) A ~~non-human animal ApoA-I protein-lipid complex comprising~~ consisting of a purified non-human animal ApoA-I protein and a lipid, wherein the lipid is sphingomyelin or dipalmitoylphosphatidylcholine, and wherein said complex activates LCAT (lecithin cholesterol acyl transferase) activity, promotes cholesterol efflux and is suitable for administration ~~in~~ to a humans.
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Currently amended) The pharmaceutical composition of Claim ~~19~~ 16 which is in the form of a solution.
22. (Withdrawn) The method of Claim 1 or 8 wherein said subject is a human.
23. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is bovine.
24. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is from chickens.
25. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is from turkeys.

26. (Withdrawn) The method of Claim 1 or 8 wherein the purified non-human animal ApoA-I protein is from pigs.
27. (Withdrawn) The method of Claim 1 or 8 wherein about 0.5 mg/kg to about 100 mg/kg of the purified non-human animal ApoA-I protein is administered to said subject.
28. (Currently amended) The method of administering the composition of Claim ~~26~~ 27 wherein the composition is administered orally.
29. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered intravenously.
30. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered by inhalation.
31. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered once daily.
32. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered twice daily.
33. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered three times daily.
34. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered four times daily.
35. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered about once weekly.
36. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered about once monthly.
37. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered about every six months.
38. (Currently amended) The method of Claim ~~26~~ 27 wherein the composition is administered about once weekly for one month.

39. (Previously presented) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 38% human lecithin-cholesterol acyltransferase (LCAT) activation activity.
40. (Previously presented) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 40% human LCAT activation activity.
41. (Previously presented) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 43% human LCAT activation activity.
42. (Previously presented) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein has greater than about 45% human LCAT activation activity.
43. (Previously presented) The pharmaceutical composition of Claim 16 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 350 mg.
44. (Previously presented) The pharmaceutical composition of Claim 43 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 35 mg.
45. (Previously presented) The pharmaceutical composition of Claim 44 wherein the non-human animal ApoA-I protein is in the amount of about 7 to about 35 mg.
46. (Currently amended) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is a bovine protein.
47. (Currently amended) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is a chicken protein.
48. (Currently amended) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is a turkey protein.
49. (Currently amended) The pharmaceutical composition of Claim 16 wherein the purified non-human animal ApoA-I protein is a porcine protein.
50. (Previously presented) The pharmaceutical composition of Claim 16 wherein said non-human animal ApoA-I protein having greater than about 60% homology with native human ApoA-I protein.

51. (Previously presented) The pharmaceutical composition of Claim 50 wherein said non-human animal ApoA-I protein having greater than about 70% homology with native human ApoA-I protein
52. (Previously presented) The pharmaceutical composition of Claim 51 wherein said non-human animal ApoA-I protein having greater than about 80% homology with native human ApoA-I protein.
53. (Previously presented) The pharmaceutical composition of Claim 52 wherein said non-human animal ApoA-I protein having greater than about 90% homology with native human ApoA-I protein.
54. (Previously presented) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 350 mg.
55. (Previously presented) The ApoA-I protein-lipid complex of Claim 54 wherein the non-human animal ApoA-I protein is in the amount of about 1 to about 35 mg.
56. (Previously presented) The ApoA-I protein-lipid complex of Claim 55 wherein the non-human animal ApoA-I protein is in the amount of about 7 to about 35 mg.
57. (Previously presented) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 38% human LCAT activation activity.
58. (Previously presented) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 40% human LCAT activation activity.
59. (Previously presented) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 43% human LCAT activation activity.
60. (Previously presented) The ApoA-I protein-lipid complex of Claim 17 wherein the non-human animal ApoA-I protein has greater than about 45% human LCAT activation activity.

61. (Previously presented) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein having greater than about 60% homology with native human ApoA-I protein.

62. (Previously presented) The ApoA-I protein-lipid complex of Claim 61 wherein said non-human animal ApoA-I protein having greater than about 70% homology with native human ApoA-I protein

63. (Previously presented) The ApoA-I protein-lipid complex of Claim 62 wherein said non-human animal ApoA-I protein having greater than about 80% homology with native human ApoA-I protein.

64. (Previously presented) The ApoA-I protein-lipid complex of Claim 63 wherein said non-human animal ApoA-I protein having greater than about 90% homology with native human ApoA-I protein.

65. (Currently amended) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is a bovine protein.

66. (Currently amended) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is a chicken protein.

67. (Currently amended) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is a turkey protein.

68. (Currently amended) The ApoA-I protein-lipid complex of Claim 17 wherein said non-human animal ApoA-I protein is a porcine protein.